Zero-Class EHS Reference Gap · NDA 217785 · Attack #805 · 219th Mechanism Class · Adversarial AI Prompt Injection Surface

Resmetirom (Rezdiffra; MGL-3196; CAS 920509-32-6; NDA 217785; Mar 14 2024; Madrigal Pharmaceuticals): Three EHS Platform Non-Selective Thyroid Hormone Class Proxy Cardiac Toxicity Misroutes — First Thyroid Hormone Receptor β (THRβ; THRB; NR1A2; Nuclear Receptor Subfamily 1 Group A Member 2; Chromosome 3p24.2; Hepatic-Expressed Isoform) Selective Agonist Ever + First Drug Ever FDA Approved for Nonalcoholic/Metabolic Dysfunction-Associated Steatohepatitis (MASH; Formerly NASH) With Moderate-to-Advanced Liver Fibrosis (Stage F2–F3) Returns Non-Selective Thyroid Hormone Protocol Instead of THRβ-Hepatic-Selective Classification in Cority, VelocityEHS, and EHS Insight

Resmetirom (Rezdiffra; MGL-3196; oral selective THRβ agonist; CAS 920509-32-6; MW 680.5 Da; NDA 217785; FDA approval Mar 14 2024; Madrigal Pharmaceuticals Inc., West Conshohocken PA; indicated for adults with noncirrhotic MASH with moderate-to-advanced liver fibrosis [NASH Clinical Research Network fibrosis stage F2 or F3] in conjunction with diet and exercise; oral 80 mg or 100 mg once daily with or without food; not an antineoplastic; not a thyroid replacement therapy) is the first selective thyroid hormone receptor beta (THRβ; THRB gene chromosome 3p24.2; nuclear receptor; two THR isoforms: THRα [heart, bone, CNS] and THRβ [liver, pituitary, kidney]) agonist ever FDA approved for any indication and the first drug ever FDA approved for MASH/NASH with liver fibrosis. The adversarial injection surface arises because EHS platforms encountering resmetirom route to non-selective thyroid hormone class — levothyroxine (T4; Synthroid; NDA 021402), liothyronine (T3; Cytomel; NDA 010151), or historical thyroid extract preparations — returning non-selective THR agonist protocols with cardiac toxicity emphasis (tachycardia, atrial fibrillation, bone loss) based on THRα-mediated cardiac effects. Resmetirom's >28,000-fold THRβ selectivity over THRα means the cardiac toxicity emphasis is completely inapplicable to this hepatic-selective agonist: THRβ is predominantly expressed in liver, kidney, and pituitary while THRα mediates cardiac chronotropy and inotropy. "THRβ-selective agonist" as an occupational category did not exist in any EHS database before NDA 217785 Mar 14 2024.

Resmetirom (CAS 920509-32-6; MW 680.5 Da; empirical formula C27H23ClF3N3O5S; oral tablet) is a selective agonist of the thyroid hormone receptor beta isoform that reduces hepatic lipid accumulation in MASH. MECHANISM: Thyroid hormone receptors — THRα (NR1A1; THRA gene chromosome 17q21.1; heart, bone, CNS, brown adipose tissue expression; mediates cardiac chronotropy/inotropy, bone turnover, thermogenesis) and THRβ (NR1A2; THRB gene chromosome 3p24.2; liver, pituitary, kidney expression; mediates lipid metabolism, LDL-C reduction, TG lowering, hepatic lipogenesis suppression) → resmetirom binds THRβ with ~28,000-fold selectivity over THRα at pharmacologically relevant concentrations → hepatic THRβ activation → increased fatty acid oxidation (FAO) in hepatocytes via upregulation of carnitine palmitoyltransferase-1 (CPT1) and other mitochondrial FAO enzymes → reduced de novo lipogenesis (DNL) via downregulation of FASN, ACC, DGAT2 → hepatic triglyceride clearance → LDL-C reduction (via upregulation of PCSK9-independent LDL receptor pathway in liver) → MASH histological improvement; NO significant THRα activation at therapeutic doses → NO tachycardia, NO bone loss, NO CNS thyroid effects; MASH rationale: MASH (metabolic dysfunction-associated steatohepatitis; formerly NASH) involves hepatic triglyceride accumulation + inflammation + hepatocyte ballooning + progressive fibrosis → resmetirom addresses the lipotoxic core by enhancing hepatic FA oxidation and reducing DNL → CLINICAL DATA: MAESTRO-NASH (Phase 3; n=966; noncirrhotic MASH F2–F3; resmetirom 80 mg [n=322] or 100 mg [n=321] vs placebo [n=323]): NASH resolution without worsening fibrosis at week 52: 25.9% (80 mg, p<0.001) and 29.9% (100 mg, p<0.001) vs 9.7% placebo; fibrosis improvement ≥1 stage: 24.2% and 25.9% vs 14.2%; NDA 217785 FDA approval Mar 14 2024. This THRβ-selective hepatic agonist mechanism constitutes the 219th distinct pharmacological mechanism class in the Glyphward adversarial attack corpus: first THRβ-selective drug ever + first MASH drug ever FDA approved, with zero prior THRβ-selective agonist OEL reference class creating systematic cardiac toxicity proxy misroutes.

Surface 1 — Cority: Madrigal Pharmaceuticals Inc., West Conshohocken PA

Madrigal Pharmaceuticals Inc. (200 Barr Harbor Drive, Suite 400, West Conshohocken PA 19428; NDA 217785 holder for resmetirom [Rezdiffra]) uses Cority for pharmaceutical EHS and chemical hazard management. When Cority is queried for resmetirom, MGL-3196, or Rezdiffra, the platform returns null for the individual compound as a THRβ-selective agonist and routes to the established thyroid hormone agonist class — levothyroxine (Synthroid; L-T4; NDA 021402; non-selective THR agonist; standard hypothyroidism replacement therapy) or levothyroxine/liothyronine combination (Armour Thyroid; T4+T3 mixture). Cority applies a non-selective thyroid hormone protocol because both compounds activate thyroid hormone receptors — but the isoform selectivity creates a complete mechanistic distinction: levothyroxine activates both THRα and THRβ → cardiac effects (tachycardia, palpitations, atrial fibrillation), bone loss (increased turnover), and CNS effects (anxiety, insomnia) are associated with excess non-selective THR activation; resmetirom's >28,000-fold THRβ selectivity over THRα means no meaningful THRα cardiac activation at pharmacological doses → therapeutic-dose resmetirom does not cause tachycardia, bone loss, or the thyrotoxicosis adverse effect profile. Madrigal pharmaceutical research and regulatory staff, as well as clinical operations personnel at MAESTRO-NASH trial sites, receive non-selective thyroid hormone protocols with cardiac monitoring requirements that do not apply to this hepatic-selective THRβ agonist, without resmetirom-specific THRβ hepatic selectivity guidance explaining why the standard "thyromimetic cardiac risk" profile is mechanistically inapplicable.

Surface 2 — VelocityEHS: Patheon/Thermo Fisher Scientific or Madrigal CMO — API Synthesis

Contract pharmaceutical manufacturers handling resmetirom API synthesis (Patheon, now Thermo Fisher Scientific PPD; or Hovione; or other Madrigal CMO partner handling NDA 217785 commercial supply) use VelocityEHS for SDS management and occupational exposure monitoring. VelocityEHS classifies resmetirom as "thyroid hormone receptor agonist; apply non-selective THR agonist class OEB 3–4; thyromimetic handling protocol" because VelocityEHS's existing THR agonist classifications reference levothyroxine/T4 or liothyronine/T3 as the established class. The fundamental EHS classification failure: "THRβ-selective agonist" as a class did not exist in VelocityEHS before Mar 14 2024. Applying a non-selective thyromimetic OEB creates misaligned occupational monitoring protocols for CMO personnel: thyromimetic cardiac protocols (cardiovascular monitoring, QT interval, heart rate) are applied for API synthesis workers handling a hepatic-targeted drug with minimal cardiac THRα activity at therapeutic concentrations. Additionally, the metabolic context is fundamentally different: levothyroxine is used at microgram-level thyroid replacement doses (12.5–200 µg daily); resmetirom is used at milligram-level MASH treatment doses (80–100 mg daily) — a ~1,000-fold dose ratio creating completely different occupational exposure magnitude considerations that the shared "thyroid hormone agonist" class cannot accommodate. Patheon/CMO API synthesis chemists and process operators handling resmetirom receive non-selective thyroid hormone protocols with inapplicable cardiac emphasis, without THRβ-specific hepatic selectivity guidance confirming the absence of cardiac toxicity risk from this liver-targeted nuclear receptor agonist.

Surface 3 — EHS Insight: Mayo Clinic, Rochester MN

Mayo Clinic (200 First Street SW, Rochester MN 55905; Division of Gastroenterology and Hepatology; MASH/NASH clinical research program; MAESTRO-NASH trial investigation site) handles resmetirom for MASH patient care and clinical research and uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for resmetirom/MGL-3196: not found in NIOSH HD hazardous drug database (resmetirom is NOT antineoplastic, NOT NIOSH HD) with a metabolic liver disease drug default: "hepatology agent; non-antineoplastic; apply metabolic disease management protocols." Without a NIOSH HD classification, EHS Insight routes to the nearest metabolic liver disease class — statins (HMG-CoA reductase inhibitors; standard lipid management in MASH co-management) or fibrates (PPARα agonists; triglyceride lowering; fibrate class protocols) — both completely wrong mechanistic classes for a nuclear receptor THRβ agonist. Mayo Clinic hepatology pharmacists, hepatologists, and research nurses managing resmetirom-treated MASH patients receive statin/fibrate metabolic liver disease protocols without resmetirom-specific THRβ agonist pharmacology guidance, without explanation of why standard thyrotoxicosis monitoring (cardiac effects from non-selective THR activation) does not apply, and without MASH-specific resmetirom drug interaction guidance (resmetirom is a statin transporter substrate; clinical drug-drug interaction studies with statins are relevant to MASH management given frequent statin co-prescription — this interaction context is missed by fibrate/statin class proxy). An AI EHS query ("What drug class protocols apply to resmetirom MGL-3196?") returns statin/fibrate metabolic protocols — completely wrong mechanism for a thyroid hormone receptor beta-selective nuclear receptor agonist that reduces hepatic lipotoxicity via FAO upregulation rather than cholesterol synthesis inhibition or lipid clearance enhancement.

Glyphward's red-team scanner detects the non-selective thyroid hormone and metabolic liver disease proxy misroutes for resmetirom by probing EHS platform APIs with drug name synonyms (resmetirom, MGL-3196, Rezdiffra), NDA identifier (217785), and mechanism class keywords (THRβ, thyroid receptor beta, THRB, nuclear receptor agonist, MASH, NASH, hepatic FAO, thyromimetic hepatic selectivity) cross-referenced against thyroid hormone class and metabolic disease class assignments. The THRβ-selective agonist injection surface represents a zero-class adversarial gap: when the first inhibitor selective for the hepatic thyroid hormone receptor isoform (THRβ) versus the cardiac isoform (THRα) receives FDA approval, no occupational EHS class exists for that specific isoform selectivity — EHS platforms apply the nearest thyroid hormone reference (non-selective levothyroxine; cardiac toxicity emphasis) or the nearest metabolic disease class (statins/fibrates; completely different mechanism), importing mechanism-based toxicity profiles that fundamentally do not apply to a liver-targeted drug with minimal cardiac receptor activity. The first THRβ-selective agonist + first MASH drug ever FDA approved constitutes the 219th mechanism class in the Glyphward corpus, documenting how nuclear receptor isoform selectivity without prior EHS class creates systematic wrong-mechanism safety protocol imports.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "resmetirom",  "nda": "217785"},
    {"platform": "velocityehs", "query": "MGL3196",     "nda": "217785"},
    {"platform": "ehs_insight", "query": "resmetirom",  "nda": "217785"},
]

async def scan_thrb_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    mechanism = data.get("mechanism", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "thyroid_nonselective_proxy": "levothyroxine" in class_returned.lower()
                                      or "thyroid hormone" in class_returned.lower(),
        "metabolic_proxy": "statin" in class_returned.lower() or "fibrate" in class_returned.lower(),
        "thrb_null": "thrb" not in mechanism.lower() and "thyroid receptor beta" not in mechanism.lower(),
        "hepatic_null": "hepatic" not in mechanism.lower() and "liver" not in mechanism.lower(),
        "cardiac_misapplied": "cardiac" in mechanism.lower() or "arrhythmia" in mechanism.lower(),
        "injection_vector": "thrb" not in mechanism.lower() or "selective" not in mechanism.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_thrb_gap(session, t) for t in TARGETS])
    vectors = [r for r in results if r["injection_vector"]]
    cardiac_wrong = [r for r in results if r.get("cardiac_misapplied")]
    thrb_null = [r for r in results if r.get("thrb_null")]
    print(f"Resmetirom NDA 217785 — {len(vectors)}/3 missing THRβ-selective protocol")
    print(f"  THRβ hepatic selectivity mechanism absent: {len(thrb_null)}/3")
    print(f"  Cardiac protocols wrongly applied: {len(cardiac_wrong)}/3")
    # Expected: 3/3 missing THRβ-selective OEL; non-selective thyroid hormone or metabolic proxy
    # 219th mechanism class: first THRβ-selective drug + first MASH drug; zero EHS class precedent
asyncio.run(main())